Stournaras C - Search Results

1

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.

Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A. Kallergi G, et al. Among authors: stournaras c. Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29383038 Free PMC article.

2

The antiglucocorticoid RU486 downregulates the expression of interleukin-2 receptors in normal human lymphocytes.

Antonakis N, Markogiannakis E, Theodoropoulou M, Georgoulias V, Stournaras C, Gravanis A. Antonakis N, et al. Among authors: stournaras c. J Steroid Biochem Mol Biol. 1991 Dec;39(6):929-35. doi: 10.1016/0960-0760(91)90351-5. J Steroid Biochem Mol Biol. 1991. PMID: 1751392

3

Interaction of captan with mammalian microtubules.

Stournaras C, Saridakis I, Fostinis Y, Georgoulias V. Stournaras C, et al. Cell Biochem Funct. 1991 Jan;9(1):23-8. doi: 10.1002/cbf.290090105. Cell Biochem Funct. 1991. PMID: 2065433

4

Triethyllead-induced inhibition of proliferation of normal human lymphocytes through decreased expression of the Tac chain of interleukin 2 receptor.

Stournaras C, Spanakis E, Perraki M, Athanasiou M, Thanos D, Georgoulias V. Stournaras C, et al. Int J Immunopharmacol. 1990;12(3):349-58. doi: 10.1016/0192-0561(90)90092-2. Int J Immunopharmacol. 1990. PMID: 2329022

5

In vitro differential effects of the antiglucocorticoid RU486 on the release of lymphokines from mitogen-activated normal human lymphocytes.

Antonakis N, Georgoulias V, Margioris AN, Stournaras C, Gravanis A. Antonakis N, et al. Among authors: stournaras c. J Steroid Biochem Mol Biol. 1994 Oct;51(1-2):67-72. doi: 10.1016/0960-0760(94)90116-3. J Steroid Biochem Mol Biol. 1994. PMID: 7947352

6

Estrogens and glucocorticoids induce the expression of c-erbB2/NEU receptor in Ishikawa human endometrial cells.

Markogiannakis E, Georgoulias V, Margioris AN, Zoumakis E, Stournaras C, Gravanis A. Markogiannakis E, et al. Among authors: stournaras c. Life Sci. 1997;61(11):1083-95. doi: 10.1016/s0024-3205(97)00617-6. Life Sci. 1997. PMID: 9307054

7

Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells.

Kallergi G, Tsapara A, Kampa M, Papakonstanti EA, Krasagakis K, Castanas E, Stournaras C. Kallergi G, et al. Among authors: stournaras c. Exp Cell Res. 2003 Aug 1;288(1):94-109. doi: 10.1016/s0014-4827(03)00210-6. Exp Cell Res. 2003. PMID: 12878162

8

Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells.

Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. Kallergi G, et al. Among authors: stournaras c. Mol Med. 2007 Jan-Feb;13(1-2):79-88. doi: 10.2119/2006-00083.Kallergi. Mol Med. 2007. PMID: 17515959 Free PMC article.

9

Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells.

Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V, Stournaras C. Kallergi G, et al. Among authors: stournaras c. Cell Physiol Biochem. 2007;20(6):977-86. doi: 10.1159/000110458. Cell Physiol Biochem. 2007. PMID: 17982280 Free article.

10

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. Kallergi G, et al. Among authors: stournaras c. Breast Cancer Res. 2008;10(5):R80. doi: 10.1186/bcr2149. Epub 2008 Sep 29. Breast Cancer Res. 2008. PMID: 18822183 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

156 results

Search Page